A Phase Ib Study to Determine the Maximum Tolerated Dose (MTD) of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2018
At a glance
- Drugs AZD-1775 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 06 Mar 2018 Planned End Date changed from 20 Apr 2018 to 19 Apr 2018.
- 23 Jan 2018 Planned End Date changed from 30 May 2018 to 20 Apr 2018.
- 23 Jan 2018 Planned primary completion date changed from 30 May 2018 to 20 Apr 2018.